Predictive Oncology (POAI)
(Delayed Data from NSDQ)
$1.51 USD
-0.15 (-9.04%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $1.63 +0.12 (7.95%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
POAI 1.51 -0.15(-9.04%)
Will POAI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for POAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for POAI
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
American Well Corporation (AMWL) Reports Q1 Loss, Lags Revenue Estimates
POAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
NantHealth, Inc. (NH) Reports Q4 Loss, Tops Revenue Estimates
1Life Healthcare, Inc. (ONEM) Reports Q4 Loss, Tops Revenue Estimates
Other News for POAI
CETX, ATNI and MNY among mid-day movers
12 Health Care Stocks Moving In Thursday's Intraday Session
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Predictive Oncology, Fujifilm enter collaboration, co-marketing agreement